SEC Tracker
Get the app
VTGN · XBRL financial data

Vistagen Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VTGN's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development3,8514,5387,437*7,64810,21511,30510,207*11,67815,91514,22313,060*10,906
General and administrative3,2073,7584,120*4,5674,1954,0494,273*4,3704,3965,6264,122*3,918
Total operating expenses7,0588,29511,556*12,21514,41015,35414,480*16,04820,31119,84917,182*14,824
Operating income (loss)(6,780)(7,884)(11,359)*(12,131)(14,227)(15,120)(14,495)*(15,804)(20,053)(19,546)(16,717)*(13,348)
Other income (expense)———000—(2)60—(1)
Income tax expense (benefit)002*0700*0007*0
Net income (loss)(6,588)(6,350)(9,521)*(10,733)(12,961)(14,089)(13,635)*(15,095)(19,417)(18,899)(16,274)*(13,030)
Earnings per share, basic‡ USD per share(0.02)(0.01)—(0.35)(0.42)(0.46)(0.43)*(0.47)(0.54)(0.45)(0.38)*(0.30)
Earnings per share, diluted USD per share(0.66)(0.22)—(0.35)(0.42)(0.46)(0.43)*(0.47)(0.54)(0.45)(0.38)*(0.30)
Weighted average shares, basic‡ thousands of shares301,577882,525—30,60330,63230,71231,573*31,93135,74942,23442,409*42,980
Weighted average shares, diluted thousands of shares10,04329,388—30,60330,63230,71231,573*31,93135,74942,23442,409*42,980
  • † Share count changed about 1/30 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (VTGN's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents37,608126,559119,166102,91884,24674,71567,13148,98562,78647,37130,78916,991
Marketable securities——05,44613,33213,84513,35114,19514,38914,39914,61414,739
Prepaid and other current assets1,3931,4801,4322,4742,3701,3811,5943,5361,7591,4751,5402,580
Total current assets39,076128,114120,672110,83899,94889,94182,07666,71678,93463,24546,94334,310
Property and equipment, net444445435489467428476530516480427375
Right-of-use asset2,0451,9341,8201,7031,5831,4611,3351,2061,074939801659
Total assets42,196131,068123,653113,548102,49692,30784,34168,92480,92965,05648,56435,736
Accounts payable1,3051,7371,5471,2097151,0396534861,8311,2801,5351,000
Accrued liabilities2931292,2352,1643,8155,4698,8106,5828,4179,2548,7559,238
Total current liabilities2,9104,1655,1236,2367,5239,62112,61211,15513,64413,52912,79511,192
Lease liability, non-current1,8541,7131,5701,4231,2691,11094878361043124963
Total liabilities6,5517,7839,3678,7459,52211,18513,95112,15914,59014,13613,04411,255
Accumulated deficit(340,343)(346,692)(356,214)(366,947)(379,908)(393,997)(407,632)(422,727)(442,144)(461,043)(477,317)(490,347)
Total stockholders' equity35,645123,285114,286104,80392,97481,12270,39056,76566,33950,92035,52024,481
Total liabilities and equity42,196131,068123,653113,548102,49692,30784,34168,92480,92965,05648,56435,736
Common shares outstanding (cover page)‡ thousands of shares811,503811,56827,02527,05527,84328,86229,15830,68039,49539,62041,03244,377
  • † Share count changed about 1/30 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (VTGN's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(6,588)(6,350)(9,521)*(10,733)(12,961)(14,089)(13,635)*(15,095)(19,417)(18,899)(16,274)*(13,030)
Stock-based compensation584*507*523*1,1601,112*1,080*963*9161,096*1,096*889*991
Depreciation and amortization32*31*33*3437*39*40*4053*54*52*52
Net cash from operating activities(6,190)*(4,535)*(7,197)*(10,869)(10,886)*(10,280)*(10,062)*(18,846)(13,759)*(17,631)*(16,200)*(14,707)
Net cash from investing activities0*(32)*(29)*(5,467)(7,786)*(422)*527*(788)(94)*104*(99)*0
Proceeds from issuing common stock34,961*210*—00*1,058*—39727,928*2,313*—928
Proceeds from issuing equity——(64)*———year only———year only—
Net cash from financing activities34,176*93,519*(168)*880*1,171*1,951*1,48827,654*2,112*(283)*909
Net change in cash27,986*88,951*(7,394)*(16,248)(18,672)*(9,531)*(7,584)*(18,146)13,801*(15,415)*(16,582)*(13,798)
  • † Share count changed about 1/30 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Vistagen Therapeutics16,991not reported(14,707)44.4M2.2 quarters 10-QJun 30, 2026
Agenus18,73834,518(31,199)*45.0M0.6 quarters 10-QJun 30, 2026
Voyager Therapeutics35,7693,165(25,842)*61.6M4.5 quarters 10-QJun 30, 2026
Eledon Pharmaceuticals6,803not reported(22,677)*81.3M3.9 quarters 10-QJun 30, 2026
Puma Biotechnology36,53756,5021,624*51.6M— 10-QJun 30, 2026
Neurogene112,485not reported(23,761)*20.0M9.5 quarters 10-QJun 30, 2026
Skye Bioscience8,068not reported(7,122)*35.4M1.4 quarters 10-QJun 30, 2026
Aclaris Therapeutics19,1671,629(19,847)*147.2M4.6 quarters 10-QJun 30, 2026
Alpha Cognition41,3846,093(6,859)*21.8M6.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.